{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:57:52Z","timestamp":1774583872170,"version":"3.50.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,1,2]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>First prospective US cooperative trial group in preneoplastic gammopathies. Prospective demonstration that genomic features of preneoplastic cells predict disease risk.<\/jats:p>","DOI":"10.1182\/blood-2013-07-515239","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T02:52:56Z","timestamp":1382410376000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":168,"title":["Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)"],"prefix":"10.1182","volume":"123","author":[{"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[{"name":"Yale Cancer Center, Yale University, New Haven, CT;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Sexton","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center\/Cancer Research and Biostatistics, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Waheed","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijay","family":"Nair","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Petty","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center\/Cancer Research and Biostatistics, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Crowley","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center\/Cancer Research and Biostatistics, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2019111816493634500_B1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111816493634500_B2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111816493634500_B3","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111816493634500_B4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111816493634500_B5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111816493634500_B6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111816493634500_B7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111816493634500_B8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.bloodjournal563521","article-title":"Localized and indolent myeloma.","volume":"56","author":"Alexanian","year":"1980","journal-title":"Blood"},{"issue":"2","key":"2019111816493634500_B9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111816493634500_B10","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111816493634500_B11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2019111816493634500_B12","author":"Chesi"},{"issue":"6","key":"2019111816493634500_B13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma.","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111816493634500_B14","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111816493634500_B15","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111816493634500_B16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111816493634500_B17","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816493634500_B18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1182\/blood-2002-06-1737","article-title":"Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.","volume":"101","author":"Zhan","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111816493634500_B19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111816493634500_B20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"Stat Soc"},{"key":"2019111816493634500_B21","author":"Crowley"},{"key":"2019111816493634500_B22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1993.10476296","article-title":"Survival by goodness of split.","volume":"88","author":"LeBlanc","year":"1993","journal-title":"J Am Stat Assoc"},{"key":"2019111816493634500_B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10485259908832799","article-title":"R2 type measure of dependence for proportional hazards models.","volume":"12","author":"Xu","year":"1999","journal-title":"J Nonparametr Statist"},{"issue":"4","key":"2019111816493634500_B24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type.","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111816493634500_B25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.","volume":"28","author":"Blad\u00e9","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816493634500_B26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions.","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2019111816493634500_B27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111816493634500_B28","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.leu.2404832","article-title":"Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2019111816493634500_B29","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"2019111816493634500_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1806.1806","article-title":"The chromosome abnormalities Del(17p), t(4;14), and +1q21 predict progression from smoldering to symptomatic multiple myeloma [abstract].","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111816493634500_B31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111816493634500_B32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.1992.tb04592.x","article-title":"Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.","volume":"82","author":"Terpstra","year":"1992","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111816493634500_B33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med"},{"issue":"6","key":"2019111816493634500_B34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2019111816493634500_B35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","article-title":"Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.","volume":"79","author":"Kyle","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2019111816493634500_B36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816493634500_B37","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111816493634500_B38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111816493634500_B39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111816493634500_B40","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2019111816493634500_B41","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111816493634500_B42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma.","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2019111816493634500_B43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/1\/78\/1373947\/78.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/1\/78\/1373947\/78.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T20:29:34Z","timestamp":1716064174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/1\/78\/32158\/Clinical-genomic-and-imaging-predictors-of-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-07-515239","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,2]]}}}